Cargando…
Pramipexole and its Extended Release Formulation for Parkinson’s Disease
Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson’s disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663603/ https://www.ncbi.nlm.nih.gov/pubmed/23861646 http://dx.doi.org/10.4137/JCNSD.S5210 |